| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $107.2M | +6.2% |
| SG&A Expense | $28.9M | +10.8% |
| Operating Income | -$136.1M | -7.1% |
| Pre-tax Income | -$129.9M | -11.2% |
| Net Income | -$129.9M | -11.2% |
| EPS (Basic) | -$3.19 | -4.6% |
| EPS (Diluted) | -$3.19 | -4.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $169.7M | +257.5% |
| Short-term Investments | $61.3M | -44.9% |
| Current Assets | $235.2M | +45.4% |
| Total Assets | $240.3M | +38.7% |
| Current Liabilities | $48.4M | +121.4% |
| Total Liabilities | $50.4M | +91.8% |
| Stockholders' Equity | $189.9M | +29.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$83.3M | +14.2% |
| Capital Expenditures | $122K | -89.2% |
| Investing Cash Flow | $52.7M | -49.4% |
| Financing Cash Flow | $152.9M | — |
| Free Cash Flow | -$83.4M | +15.0% |